ORGANIZATION

• Takata Pharma President Hiroki Takada Becomes New JGA Chief
  June 1, 2022

• FPMAJ Chief Vows to Go on Offensive in Pricing Debate, Flags Japan’s Decline in Global Market
  May 30, 2022

• JMA President Hopeful Matsumoto Vows to Boost Collaboration with Doctors, Govt; Matsubara Files for Election
  May 25, 2022

• JMA Chief Nakagawa Drops Bid for Re-Election, Matsumoto Is Likely Winner
  May 24, 2022

• PhRMA Hails Launch of Indo-Pacific Economic Framework
  May 24, 2022

• INES-Led Coalition Calls for Patient/Citizen Participation in Healthcare Policymaking
  May 23, 2022

• Japan, US, European Pharma Groups Prod Price Maintenance of Patented Drugs in Joint Pitch towards Honebuto
  May 17, 2022

• PhRMA Urges Japan to Exclude Patented Products from Off-Year Re-Pricing in 2023, Create Innovation Ecosystem
  May 17, 2022

• JPMA Takes Issue with WTO IP Waiver Proposal for COVID Vaccines
  May 13, 2022

• Lagevrio Given to 87,000 via Pharmacies, Paxlovid to 120 as of April 15
  May 9, 2022

• FPMAJ Official Prods Rethink of Off-Year Price Revision as Ukraine War Pushes Up Costs
  April 27, 2022

• JPMA Think Tank Analyzing Cause of Expanding Drug Lag, Over 70% of US/EU Approved Meds Not Available in Japan
  April 27, 2022

• JGA Suspends Kyowa Pharma for 5 Years after GMP Violations
  April 25, 2022

• Predictability of Drug Pricing Must Be Ensured: EFPIA Japan Director General
  April 22, 2022

• Mediceo Dodged Charges and FTC Penalties, but Still Barred from JCHO Bids
  April 12, 2022

• FPMAJ Looks into Impact of Shanghai COVID-19 Lockdown
  April 11, 2022

• Asian Pharma Groups to Boost Drug Discovery Collab via RWD Use
  April 7, 2022

• Drug Damage Watchdog Calls for Temporary Suspension of Lagevrio Use
  April 6, 2022

• JPMA Chief Sees Free Pricing Proposal as Catalyst for Active Reform Debate
  April 5, 2022

• Stop Avigan Stockpiling, Revoke Flu Approval: Drug Damage Watchdog
  April 5, 2022

ページ

• « 先頭
• ‹ Prev
• …
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• …
• Next ›
• 最終 »